CA1105835A - Comprime pharmaceutique contenant un anti-allergique - Google Patents

Comprime pharmaceutique contenant un anti-allergique

Info

Publication number: CA1105835A
Authority: CA; Canada
Prior art keywords: formulation according; active ingredient; tetrahydro; oxo; pyran
Prior art date: 1976-05-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA278,833A

Other languages

English (en)

Inventor

John N.C. Healey

Anthony W. Jenkins

Thomas J. Sullivan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fisons Ltd

Original Assignee

Fisons Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-05-21

Filing date

1977-05-19

Publication date

1981-07-28

1977-05-19 Application filed by Fisons Ltd filed Critical Fisons Ltd

1981-07-28 Application granted granted Critical

1981-07-28 Publication of CA1105835A publication Critical patent/CA1105835A/fr

Status Expired legal-status Critical Current

Links

239000000043 antiallergic agent Substances 0.000 title claims abstract description 7
239000000203 mixture Substances 0.000 claims abstract description 42
239000004480 active ingredient Substances 0.000 claims abstract description 37
238000009472 formulation Methods 0.000 claims abstract description 30
239000000463 material Substances 0.000 claims abstract description 25
239000003085 diluting agent Substances 0.000 claims abstract description 18
239000002253 acid Substances 0.000 claims abstract description 17
239000011230 binding agent Substances 0.000 claims abstract description 12
239000000314 lubricant Substances 0.000 claims abstract description 12
230000000694 effects Effects 0.000 claims abstract description 11
208000010668 atopic eczema Diseases 0.000 claims abstract description 10
230000000172 allergic effect Effects 0.000 claims abstract description 9
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims abstract description 9
206010067484 Adverse reaction Diseases 0.000 claims abstract description 7
-1 activity Chemical compound 0.000 claims abstract description 7
230000006838 adverse reaction Effects 0.000 claims abstract description 7
229960000265 cromoglicic acid Drugs 0.000 claims abstract description 7
239000007916 tablet composition Substances 0.000 claims abstract description 6
DLKZWVIRKURGIR-UHFFFAOYSA-N 4-oxo-10-propyl-6,7,8,9-tetrahydrobenzo[g]chromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1CCCCC1=C2 DLKZWVIRKURGIR-UHFFFAOYSA-N 0.000 claims abstract description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
239000007884 disintegrant Substances 0.000 claims description 7
229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
239000008108 microcrystalline cellulose Substances 0.000 claims description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 5
229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
VFFTVZUIDYJUQS-UHFFFAOYSA-N 5-hydroxy-4-oxo-10-propyl-6,7,8,9-tetrahydrobenzo[g]chromene-2-carboxylic acid Chemical group O1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1CCCCC1=C2O VFFTVZUIDYJUQS-UHFFFAOYSA-N 0.000 claims description 4
FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
229920000609 methyl cellulose Polymers 0.000 claims description 3
239000001923 methylcellulose Substances 0.000 claims description 3
235000010981 methylcellulose Nutrition 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
239000000377 silicon dioxide Substances 0.000 claims description 3
235000012239 silicon dioxide Nutrition 0.000 claims description 3
QFZTUWOWMRNMAH-UHFFFAOYSA-N 2h-pyran-2-carboxylic acid Chemical compound OC(=O)C1OC=CC=C1 QFZTUWOWMRNMAH-UHFFFAOYSA-N 0.000 claims description 2
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
229920003086 cellulose ether Polymers 0.000 claims description 2
235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
239000002552 dosage form Substances 0.000 abstract description 10
206010020751 Hypersensitivity Diseases 0.000 abstract description 4
230000007815 allergy Effects 0.000 abstract description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 8
235000021355 Stearic acid Nutrition 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
239000008117 stearic acid Substances 0.000 description 7
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
229920000168 Microcrystalline cellulose Polymers 0.000 description 6
150000002148 esters Chemical class 0.000 description 5
206010002198 Anaphylactic reaction Diseases 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
230000036783 anaphylactic response Effects 0.000 description 4
208000003455 anaphylaxis Diseases 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
239000008101 lactose Substances 0.000 description 4
238000002156 mixing Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229920002472 Starch Polymers 0.000 description 3
230000002009 allergenic effect Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
229940032147 starch Drugs 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
241000700199 Cavia porcellus Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
229920003072 Plasdone™ povidone Polymers 0.000 description 2
230000002411 adverse Effects 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
125000005907 alkyl ester group Chemical group 0.000 description 2
230000001078 anti-cholinergic effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
230000001713 cholinergic effect Effects 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
230000008602 contraction Effects 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
238000007908 dry granulation Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
VDSILRLWKIEHRV-UHFFFAOYSA-N 3-nitro-3h-indene-1,2-dione Chemical class C1=CC=C2C([N+](=O)[O-])C(=O)C(=O)C2=C1 VDSILRLWKIEHRV-UHFFFAOYSA-N 0.000 description 1
241000220479 Acacia Species 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
239000004135 Bone phosphate Substances 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010036774 Proctitis Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
125000005041 acyloxyalkyl group Chemical group 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229940109248 cromoglycate Drugs 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000007580 dry-mixing Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
229930003944 flavone Natural products 0.000 description 1
150000002213 flavones Chemical class 0.000 description 1
235000011949 flavones Nutrition 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
150000002641 lithium Chemical class 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
238000000465 moulding Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002916 oxazoles Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
150000005041 phenanthrolines Chemical class 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000009725 powder blending Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
229960004274 stearic acid Drugs 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
229940033134 talc Drugs 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
150000007964 xanthones Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA278,833A 1976-05-21 1977-05-19 Comprime pharmaceutique contenant un anti-allergique Expired CA1105835A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB20984/76		1976-05-21
GB20984/76A GB1570993A (en)	1976-05-21	1976-05-21	Pharmaceutical tablet formulation

Publications (1)

Publication Number	Publication Date
CA1105835A true CA1105835A (fr)	1981-07-28

Family

ID=10155196

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA278,833A Expired CA1105835A (fr)	1976-05-21	1977-05-19	Comprime pharmaceutique contenant un anti-allergique

Country Status (17)

Country	Link
JP (1)	JPS52143220A (fr)
AU (1)	AU511269B2 (fr)
BE (1)	BE854690A (fr)
CA (1)	CA1105835A (fr)
DE (1)	DE2722917A1 (fr)
DK (1)	DK218777A (fr)
FI (1)	FI771587A7 (fr)
FR (1)	FR2426460A1 (fr)
GB (1)	GB1570993A (fr)
IE (1)	IE45282B1 (fr)
IL (1)	IL52102A0 (fr)
LU (1)	LU77369A1 (fr)
NL (1)	NL7705560A (fr)
NO (1)	NO771765L (fr)
NZ (1)	NZ184141A (fr)
SE (1)	SE7705850L (fr)
ZA (1)	ZA772989B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1595220A (en) *	1977-12-23	1981-08-12	Fisons Ltd	Tablets containing 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane
US5447728A (en) *	1992-06-15	1995-09-05	Emisphere Technologies, Inc.	Desferrioxamine oral delivery system
IL158390A0 (en)	2001-05-01	2004-05-12	Pfizer Prod Inc	Method for manufacturing a low dose pharmaceutical composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA753210B (en) *	1974-06-14	1976-04-28	Upjohn Co	Novel dosing regimen for intal biologues
IE41922B1 (en) *	1974-11-09	1980-04-23	Fisons Ltd	Pharmaceutical compositions containing bis-chromones
FR2292468A1 (fr) *	1974-11-30	1976-06-25	Fisons Ltd	Monochromes

1976
- 1976-05-21 GB GB20984/76A patent/GB1570993A/en not_active Expired
1977
- 1977-05-16 FR FR7714858A patent/FR2426460A1/fr active Granted
- 1977-05-16 IL IL52102A patent/IL52102A0/xx unknown
- 1977-05-16 BE BE177619A patent/BE854690A/fr unknown
- 1977-05-17 AU AU25214/77A patent/AU511269B2/en not_active Expired
- 1977-05-17 SE SE7705850A patent/SE7705850L/xx unknown
- 1977-05-18 NZ NZ184141A patent/NZ184141A/xx unknown
- 1977-05-18 DK DK218777A patent/DK218777A/da not_active Application Discontinuation
- 1977-05-18 LU LU77369A patent/LU77369A1/xx unknown
- 1977-05-18 ZA ZA00772989A patent/ZA772989B/xx unknown
- 1977-05-19 FI FI771587A patent/FI771587A7/fi not_active Application Discontinuation
- 1977-05-19 JP JP5712777A patent/JPS52143220A/ja active Pending
- 1977-05-19 CA CA278,833A patent/CA1105835A/fr not_active Expired
- 1977-05-20 NO NO771765A patent/NO771765L/no unknown
- 1977-05-20 IE IE1038/77A patent/IE45282B1/en unknown
- 1977-05-20 NL NL7705560A patent/NL7705560A/xx not_active Application Discontinuation
- 1977-05-20 DE DE19772722917 patent/DE2722917A1/de not_active Ceased

Also Published As

Publication number	Publication date
AU2521477A (en)	1978-11-23
FR2426460B1 (fr)	1983-04-29
AU511269B2 (en)	1980-08-07
IE45282B1 (en)	1982-07-28
FI771587A7 (fr)	1977-11-22
IL52102A0 (en)	1977-07-31
ZA772989B (en)	1978-04-26
GB1570993A (en)	1980-07-09
IE45282L (en)	1977-11-21
JPS52143220A (en)	1977-11-29
SE7705850L (sv)	1977-11-22
DE2722917A1 (de)	1977-12-01
LU77369A1 (fr)	1977-12-13
FR2426460A1 (fr)	1979-12-21
NZ184141A (en)	1979-06-19
NO771765L (no)	1977-11-22
DK218777A (da)	1977-11-22
NL7705560A (nl)	1977-11-23
BE854690A (fr)	1977-11-16

Legal Events

Date	Code	Title	Description
1998-07-28	MKEX	Expiry

Publication	Publication Date	Title
KR0136279B1 (ko)	1998-04-25	일정수분을 함유하는 서방형 제제
US20030096791A1 (en)	2003-05-22	Taste masking of highly water-soluble drugs
IL110376A (en)	1998-08-16	Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
CA2644179C (fr)	2018-09-25	Composition pharmaceutique inedite comprenant une matrice de desintegration
US3849561A (en)	1974-11-19	Anti-peptic ulcer substance from corydalis tubers
JPS5810513A (ja)	1983-01-21	新規なベンドロフルメチアジド配合物およびその調整方法
EP0571973A2 (fr)	1993-12-01	Comprimé au valproate de sodium à libération lente
CA2764172A1 (fr)	2010-12-16	Antagoniste du recepteur de la thrombine et comprime de clopidogrel a dose fixe
JP2001503734A (ja)	2001-03-21	カリウム、ナトリウムおよびトリスオキサプロジン塩医薬組成物
AU615950B2 (en)	1991-10-17	Pharmaceutical composition for piperidinoalkanol derivatives
US4428951A (en)	1984-01-31	Long acting pharmaceutical composition
US3224940A (en)	1965-12-21	Antacid compositions and method of using same
TW200304807A (en)	2003-10-16	Sleeping medicine formed by coating solid
EP0192321A2 (fr)	1986-08-27	Compositions pharmaceutiques avec enrobage entérique contenant des allergènes
GB1570993A (en)	1980-07-09	Pharmaceutical tablet formulation
DE2950154A1 (de)	1980-07-10	Neue galenische zubereitungen
EP0121901A1 (fr)	1984-10-17	Pastilles à libération contrôlée indépendante du PH
FI82377C (fi)	1991-03-11	Foerfarande foer framstaellning av ett med baser bildat piroxicamsalt utfaellt pao en farmaceutiskt godtagbar baerare.
GB1570994A (en)	1980-07-09	Pharmaceutical formulation
CA2469736A1 (fr)	2003-10-23	Compositions de formes dosifiees solides de tannate de diphenhydramine et procedes d'utilisation associes
GB2061111A (en)	1981-05-13	Long acting pharmaceutical composition
IE45283B1 (en)	1982-07-28	Pharmaceutical formulation
JPH0737383B2 (ja)	1995-04-26	胃酸分泌抑制剤含有固型製剤
JPH02282322A (ja)	1990-11-19	有効物質の浸食制御による放出システムおよびその製造方法
CN106474122B (zh)	2020-04-14	一种阿莫西林克拉维酸钾的药物组合物及其应用